139 related articles for article (PubMed ID: 11900227)
1. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.
Hsu C; Huang CL; Hsu HC; Lee PH; Wang SJ; Cheng AL
Cancer; 2002 Jan; 94(2):415-20. PubMed ID: 11900227
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
3. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Sasai K; Tsurumaru M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):203-11. PubMed ID: 15629613
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
Pegram MD; Slamon DJ
Semin Oncol; 1999 Aug; 26(4 Suppl 12):89-95. PubMed ID: 10482199
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
8. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
9. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
10. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
13. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway.
Witters L; Engle L; Lipton A
Oncol Rep; 2002; 9(6):1163-6. PubMed ID: 12375012
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
[TBL] [Abstract][Full Text] [Related]
17. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
Brodowicz T; Kandioler D; Tomek S; Ludwig C; Rudas M; Kunstfeld R; Koestler W; Hejna M; Budinsky A; Wiltschke C; Zielinski CC
Br J Cancer; 2001 Nov; 85(11):1764-70. PubMed ID: 11742500
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.
Pratesi G; Petrangolini G; Tortoreto M; Addis A; Zunino F; Calcaterra C; Merlo A; Tagliabue E; Menard S; Balsari A
J Immunother; 2008; 31(6):537-44. PubMed ID: 18528301
[TBL] [Abstract][Full Text] [Related]
19. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
[TBL] [Abstract][Full Text] [Related]
20. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
Taylor C; Hershman D; Shah N; Suciu-Foca N; Petrylak DP; Taub R; Vahdat L; Cheng B; Pegram M; Knutson KL; Clynes R
Clin Cancer Res; 2007 Sep; 13(17):5133-43. PubMed ID: 17785568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]